Managing Early Ejaculation: What Does the Future Hold?Premature ejaculation PE is a common male sexual dysfunction. Once the diagnosis of PE is established through a thorough history, a variety of medical therapies is available, including tricyclic antidepressants, selective serotonin reuptake inhibitors SSRIs , centrally acting opiates, phosphodiesterase 5 inhibitors and topical desensitizing creams. Most of these treatments increase the intravaginal ejaculation latency time IELT and patient satisfaction scores, with the most convincing evidence for SSRIs and topical creams. Daily SSRIs such as paroxetine, although efficacious, do have a substantial and prolonged side effect profile. In the near future, the topical aerosol PSD is due to be licensed for the treatment of PE, increasing IELT by up to a factor of 6 but having minimal local and negligible systemic side effects. Premature ejaculation PE can be a debilitating male sexual impairment. This wide range can be partly attributed to variations in the way that PE is defined, but may also reflect differences between populations and differences in the degree of bother.
How to overcome Premature Ejaculation – effective treatments and techniques
Medically reviewed by Drugs. Last updated on May 30, Premature ejaculation occurs when a man reaches orgasm and ejaculates too quickly and without control. In other words, ejaculation occurs before a man wants it to happen. It may occur before or after beginning foreplay or intercourse. Some men experience a lot of personal distress because of this condition. As many as one in five men experience difficulty with uncontrolled or early ejaculation at some point in life.
Message sent successfully
Recent attention in the field of male sexual dysfunction has focused on erectile dysfunction. However, premature ejaculation PE is an extremely common condition that warrants clinical study and exploration of pharmacologic treatments. Until recently, PE was thought to be a behavioral problem for which the best remedy was a learned control technique. However, some drugs currently on the market, including sildenafil and the selective serotonin reuptake inhibitors, appear to have efficacy in the treatment of PE. More research is needed before FDA approval of such agents for this indication, but more and better options for men with PE are anticipated as attention to ejaculatory disorders grows and, hopefully, the associated stigma decreases.